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b-site APP cleaving enzyme-1 (BACE1), the rate-
limiting enzyme for b-amyloid (Ab) production, is
elevated in Alzheimer’s disease (AD). Here, we show
that energy deprivation induces phosphorylation of
the translation initiation factor eIF2a (eIF2a-P), which
increases the translation of BACE1. Salubrinal, an
inhibitor of eIF2a-P phosphatase PP1c, directly
increases BACE1 and elevates Ab production in
primary neurons. Preventing eIF2a phosphorylation
by transfection with constitutively active PP1c regu-
latory subunit, dominant-negative eIF2a kinase
PERK, or PERK inhibitor P58IPK blocks the energy-
deprivation-induced BACE1 increase. Furthermore,
chronic treatment of aged Tg2576 mice with energy
inhibitors increases levels of eIF2a-P, BACE1, Ab,
and amyloid plaques. Importantly, eIF2a-P and
BACE1 are elevated in aggressive plaque-forming
5XFAD transgenic mice, and BACE1, eIF2a-P, and
amyloid load are correlated in humanswithAD. These
results strongly suggest that eIF2a phosphorylation
increases BACE1 levels and causes Ab overproduc-
tion, which could be an early, initiating molecular
mechanism in sporadic AD.
INTRODUCTION
Alzheimer’s disease is a devastating neurodegenerative brain
disorder of the elderly for which no cure or disease-modifying
treatment exists. A major histopathological hallmark of AD is
the amyloid plaque, composed of the Ab peptide (Glenner and
Wong, 1984). Ab appears to play a critical, early role in the path-
ogenesis of AD, because all known familial forms of AD (FAD)
result from autosomal-dominant mutations that enhance pro-
amyloidogenic processing of APP (Hardy and Selkoe, 2002;988 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.Younkin, 1998). Although the mechanisms of Ab overproduction
in FAD are fairly well understood, little is known about the
cause(s) of sporadic AD (SAD), which is the predominant form
of AD. However, based on the strong genetic association of Ab
with FAD and the clinical and pathological similarities between
FAD and SAD, it is likely that Ab is also involved in SAD patho-
genesis at an early stage.
b-Amyloid is generated from the sequential proteolytic pro-
cessing of amyloid precursor protein (APP) by the enzymes
b- and g-secretase (De Strooper, 2003; Sisodia and St George-
Hyslop, 2002). b-Secretase was identified as the transmembrane
aspartic protease, BACE1, responsible for initiating cleavage of
APP to form Ab (Hussain et al., 1999; Lin et al., 2000; Sinha
et al., 1999; Vassar et al., 1999; Yan et al., 1999). Because of
its central role in the amyloidogenic process, BACE1 is a prom-
ising drug target for AD therapy (Laird et al., 2005; Luo et al.,
2001; Ohno et al., 2006; Ohno et al., 2004; Singer et al., 2005;
Vassar et al., 1999). The K670N, M671L (Swedish) mutation in
APP (APPsw) promotes cleavage of APP by BACE1, increases
total Ab production, and causes FAD (Citron et al., 1992),
implying that increased BACE1 activity might be sufficient to
induce AD pathogenesis. Importantly, recent studies have
shown that BACE1 levels and activity are increased in post-
mortem AD brain samples (Fukumoto et al., 2002; Holsinger
et al., 2002; Li et al., 2004; Sennvik et al., 2004; Tyler et al.,
2002; Yang et al., 2003; Zhao et al., 2007), suggesting that
elevated BACE1 levels in the brain might play a role in the devel-
opment of SAD. Most studies show that BACE1 mRNA levels are
not increased in AD brain, indicating that a posttranscriptional
mechanism causes the BACE1 increase.
One factor that appears closely associated with AD is impaired
cerebral energy metabolism. Positron emission tomography
(PET) imaging studies have shown that glucose utilization is
dramatically lower in AD brain than in age-matched, nonde-
mented brain (de Leon et al., 2007; Mosconi et al., 2007). More-
over, postmortem analysis of AD brain shows downregulated
expression of mitochondrial enzymes (de Leon et al., 1983;
Rapoport, 1999a, 1999b), indicating that energy metabolism
might be deficient in AD. Aging, the primary risk factor for
Neuron
Phosphorylated eIF2a Increases BACE1 and Ab LevelsSAD, is also a major risk factor for cardiovascular and cerebro-
vascular disease (Cole and Vassar, 2008; Decarli, 2004),
implying that low-level chronically reduced glucose and oxygen
delivery to the brain might contribute to the development of AD.
Importantly, young and middle-aged nondemented carriers of
the apolipoprotein E4 (ApoE4) allele, a major genetic risk factor
for AD, and patients with mild cognitive impairment (MCI),
a condition that precedes clinical AD, also exhibit reduced brain
glucose utilization by PET imaging (Reiman et al., 2004; Wolf
et al., 2003), suggesting that impaired cerebral energy metabo-
lism might be an early event in AD pathogenesis rather than
a downstream consequence of neurodegeneration.
We have shown previously, using an acute pharmacological
model of energy metabolism inhibition in preplaque APP-overex-
pressing transgenic mice (Tg2576), that BACE1 and Ab levels
become elevated posttranscriptionally in the brain, indicating
that energy deprivation might be amyloidogenic in vivo (Velli-
quette et al., 2005). These data lend further support to a growing
body of evidence that BACE1 might play a normal physiological
role in the cellular stress response (Kamenetz et al., 2003; Tam-
agno et al., 2005; Tesco et al., 2007; Velliquette et al., 2005; Wen
et al., 2004; Wen et al., 2008; Yang et al., 2003; Zhao et al., 2007).
Two different hypotheses have emerged to explain how BACE1
might be posttranscriptionally regulated in response to stress or
aging: alterations in microRNA profiles and apoptosis-depen-
dent changes in BACE1 protein stability (Hebert et al., 2008;
Tesco et al., 2007; Wang et al., 2008). One other area that
remains unexplored is the possible role of stress-induced alter-
ations in the translational control of the BACE1 transcript.
Stress-induced changes in the translation initiation machinery
and a subsequent shift to selective translation of stress-
response transcripts is a widely known phenomenon (Holcik
and Sonenberg, 2005; Pavitt, 2005; Schroder and Kaufman,
2006). Furthermore, recent studies have shown that the BACE1
mRNA 50-untranslated region (50UTR) acts as a translational
repressor (De Pietri Tonelli et al., 2004; Lammich et al., 2004; Mi-
hailovich et al., 2007; Rogers et al., 2004; Zhou and Song, 2006).
This property of the BACE1 mRNA 50 UTR appears to be related
to the fact that it is long, GC-rich, possesses extensive
secondary structure, and contains 3 upstream open reading
frames (uORFs), characteristics shared with many 50 UTRs of
transcripts that are translationally controlled by cellular stress.
In addition, it has been shown that regulation of energy stores
and translational control of proteins are intricately related
(Harding et al., 2001; Lee, 2001; Scheuner et al., 2001). Taken
together, these results suggest the intriguing possibility that
the BACE1 increase in AD might be the result of translational
derepression of the BACE1 mRNA 50 UTR induced by energy
metabolism stress, a mechanism that could have important
implications for AD pathogenesis.
To identify the molecular mechanism underlying elevated
BACE1 levels in response to energy inhibition, we used glucose
deprivation in cell culture as an in vitro model of energy defi-
ciency. In stable BACE1-expressing HEK293 cells and primary
mouse cortical neurons, glucose deprivation caused a posttran-
scriptional increase in BACE1 level that correlated with
enhanced phosphorylation of the translation initiation factor
eIF2a, a well-established mechanism of stress-induced transla-tional control (Clemens, 2001; Schroder and Kaufman, 2006).
Direct pharmacologic induction of eIF2a phosphorylation
elevated BACE1 levels and enhanced Ab production, and
conversely, genetic inhibition of eIF2a phosphorylation pre-
vented the BACE1 increase under conditions of energy depriva-
tion in vitro. Additionally, chronic energy deprivation in vivo
increased eIF2a-P and BACE1 levels, and exacerbated amyloid
pathology in Tg2576 mice. Elevated eIF2a-P and BACE1 levels
were also observed in another APP transgenic with aggressive
amyloid pathology (5XFAD) and in human AD brain. We conclude
that eIF2a phosphorylation increases BACE1 levels via a transla-
tional control mechanism and promotes amyloidogenesis in
response to energy deprivation, and that this mechanism might
play an important role in sporadic AD pathogenesis.
RESULTS
Energy Deprivation Increases BACE1 Levels
by a Translational Mechanism
Previously, we observed increased BACE1 protein levels in the
absence of increased BACE1 mRNA levels after acute energy
inhibitor treatment in mice, suggesting a posttranscriptional
mechanism (Velliquette et al., 2005). To investigate the molecular
mechanism responsible for raising the BACE1 level in response
to energy inhibition, we used HEK293 cells that stably overex-
press the entire 2.5 kb human BACE1 transcript, including the
complete 50 and 30 UTRs, driven by the CMV promoter
(BACE1-293 cells). BACE1-293 cells are ideal for investigating
BACE1 posttranscriptional mechanisms because the cell line
expresses BACE1 mRNA from a constitutive heterologous
promoter that is transcriptionally stable under a wide range of
conditions, and it expresses BACE1 mRNA with the endogenous
50 and 30 UTRs that are required for the normal translational regu-
lation of BACE1 mRNA. We treated BACE1-293 cells for 2 to
48 hr in media containing 25 mM glucose (CON) or lacking
glucose (NG) and analyzed BACE1 levels in lysates by immuno-
blot (Figures 1A and 1B). Energy deprivation slowed cell growth
but was otherwise nontoxic, as indicated by failure to activate
caspase 3 (see Figure S2 [available online]). BACE1 levels in
NG-treated cells showed a clear upward trend at 2 hr that became
statistically significant at 6 hr and peaked around 12 hr (Figures
1A and 1B; p < 0.001). The glucose-deprivation-induced
BACE1 increase plateaued at 150%–170% of control (CON)
levels and remained high for the duration of the experiment.
Importantly, the early increase in BACE1 levels after glucose
deprivation suggested a posttranscriptional mechanism.
Although the constitutively active CMV promoter made it
unlikely that increased BACE1 gene transcription was the cause
of the glucose-deprivation-induced BACE1 elevation, we sought
to definitively exclude this possibility by treating BACE1-293
cells with the transcriptional inhibitor actinomycin D (ActD) in
the presence or absence of glucose (Figures 1C–1E). First, it is
relevant to note that 12 hr of NG treatment of BACE1-293 cells
on its own did not increase steady-state BACE1 mRNA levels
relative to control treated cells (Figure 1E, two left bars), even
though BACE1 protein levels were significantly elevated
(Figure 1D, two left bars). Most importantly, ActD treatment failed
to prevent BACE1 levels from increasing in cells incubated in NGNeuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 989
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cells regardless of whether they were exposed to ActD (Figures
1C–1D). This is a striking result, given that ActD dramatically
reduced BACE1 mRNA levels in cells either incubated with or
without glucose, as determined by BACE1 primer-specific Taq-
Man quantitative real-time PCR (Figure 1E, two right bars). These
results conclusively demonstrate that the BACE1 increase
induced by energy deprivation in BACE1-293 cells was the result
of a posttranscriptional mechanism and was not due to either
elevated BACE1 transgene mRNA synthesis or increased
BACE1 mRNA stability.
Recent studies have shown that BACE1 protein stability can
be modulated by the lysosomal and ubiquitin-proteasomal
degradation pathways (Koh et al., 2005; Qing et al., 2004; Tesco
et al., 2007). To determine whether increased BACE1 protein
stability was the posttranscriptional mechanism underlying the
BACE1 increase in response to energy deprivation, we used
pulse-chase 35S-metabolic radiolabeling to measure the half-
life (t1/2) of BACE1 protein in BACE1-293 cells incubated under
normal chase conditions compared with cells chased in NG
media or in media containing 2-deoxyglucose (2DG), which
competes with glucose for catabolism by hexokinase. We
Figure 1. Glucose Deprivation Increases
BACE1 Protein Levels in BACE1-293 Cells
via a Posttranscriptional Mechanism
(A) BACE1-293 cells were incubated for 2, 6, 12,
24, 36, and 48 hr in either normal DMEM with
glucose (25 mM; CON) or DMEM without glucose
(NG). Cells were lysed at the end of the treatment
periods and 5 mg total protein per lane was used
for immunoblot analysis of BACE1. b-actin was
used as a loading control.
(B) BACE1 immunosignals in (A) were quantified by
phosphorimager, normalized to b-actin, and ex-
pressed as percentage of control (CON) for each
time point. BACE1 protein levels were significantly
elevated compared with CON in response to
glucose deprivation from 6–48 hr (mean ± SEM;
*p < 0.05; **p < 0.01; ***p < 0.001). An upward
trend for a BACE1 increase was present at 2 hr
of NG treatment (n = 3 per group).
(C) Triplicate wells of BACE1-293 cells were incu-
bated for 12 hr in regular DMEM with glucose
(CON), DMEM without glucose (NG), DMEM with
glucose containing 1.7 mg/ml actinomycin D
(ActD), or DMEM without glucose containing
1.7 mg/ml actinomycin D (ActD + NG). Cells were
lysed at the end of the treatment period and 5 mg
total protein was used for immunoblot analysis of
BACE1. b-actin was used as a loading control.
(D) BACE1 immunosignals in (C) were quantified
by phosphorimager, normalized to b-actin, and
expressed as percentage of control (CON).
BACE1 protein levels were significantly elevated
in response to 12 hr of NG treatment either in the
presence or absence of ActD, compared with
CON (*p < 0.05), demonstrating that BACE1 gene transcription was not required for the BACE1 increase. BACE1 protein levels were significantly decreased
with 12 hr of ActD treatment alone, compared with CON (mean ± SEM; #p < 0.05; n = 3 per group).
(E) Parallel BACE1-293 cell cultures were treated as in (C), except that total mRNA was isolated and levels of BACE1 mRNA measured via the TaqMan real-time
PCR relative quantification method and expressed as percentage of control (CON; n = 6). There were no differences in BACE1 mRNA levels between cells treated
in media with or without glucose, verifying that NG treatment did not increase BACE1 gene transcription or mRNA stability. Note that ActD performed as expected
and produced a robust decrease of BACE1 mRNA in cells treated with or without glucose, compared with CON (mean ± SEM; ##p < 0.01).
(F) BACE1-293 cells were pulse-labeled in media containing 35S-methionine/cytseine and chased for up to 24 hr in normal DMEM with glucose (CON), DMEM
without glucose (NG), or DMEM containing 50 mM 2-deoxyglucose (2-DG). Radiolabeled BACE1 was immunoprecipitated from cell lysates at 0, 3, 6, 12, and 24 hr
after labeling, separated via SDS-PAGE, and visualized by autoradiography. Note that immaturely glycosylated BACE1 is 60 kDa, whereas maturely glycosy-
lated BACE1 is 70 kDa. There were no apparent differences between the half-lives of BACE1 protein under CON, NG, and 2DG conditions, indicating that
BACE1 increases are not due to BACE1 protein stabilization.
(G) HEK293 cells were transiently transfected with pcDNA3.1Zeo(+) vector containing the entire human BACE1 coding region (1.5 kb) plus the BACE1 50UTR
(+50UTR) or pcDNA3.1Zeo(+) vector containing only the human BACE1 coding region (50UTR; (Lammich et al., 2004). After overnight recovery, cells were incu-
bated for 24 hr in normal DMEM with glucose (CON) or DMEM without glucose (NG). Cell lysates were prepared and 5 mg total protein per lane was used for
immunoblot analysis of BACE1 and b-actin. Note that transfection with the 50UTR construct caused the accumulation of immature 60 kDa BACE1, in addition
to mature 70 kDa BACE1 (Haniu et al., 2000).
(H) BACE1 immunosignals in (G) were normalized to b-actin and expressed as percentage of +50UTR control (CON, +50UTR). The glucose-deprivation-induced
BACE1 increase did not occur in the absence of the BACE1 50UTR, implicating a BACE1 50UTR-dependent translational control mechanism (n = 3 per group; **,
comparison between CON and NG, +50UTR; p < 0.01; mean ± SEM). Error bars represent SEM in all histograms.990 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.
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previous reports (Haniu et al., 2000; Huse et al., 2000). Impor-
tantly, under NG or 2DG chase conditions, we found that the
t1/2 of BACE1 was similar to control (Figure 1F), indicating that
increased BACE1 protein stability is not the posttranscriptional
mechanism responsible for elevated BACE1 levels in response
to energy deficiency.
Taken together, our results thus far excluded gene transcrip-
tion, mRNA stability, and protein stability as causes of the
energy-deprivation-induced BACE1 increase, suggesting that
the BACE1 increase was likely to occur by a translational mech-
anism. In support of this notion, recent studies have shown that
translation is inhibited by the BACE1 mRNA 50 UTR, which is long
(453 nts), GC-rich (77%), is predicted to have extensive
secondary structure, and contains 3 uORFs (De Pietri Tonelli
et al., 2004; Lammich et al., 2004; Mihailovich et al., 2007;
Rogers et al., 2004; Zhou and Song, 2006). These characteristics
of the BACE1 50UTR are typical of translationally regulated stress
response mRNAs (Clemens, 2001), suggesting that the BACE1
transcript might be a target of translational control by one or more
stress-activated pathways. However, previous studies had not
addressed whether BACE1 was regulated by stress-induced
translational pathways, and if so, whether BACE1 translational
control could be relevant to AD pathogenesis. To initially test
these hypotheses, we investigated whether the BACE1 mRNA
50UTR was required for the energy-deprivation-dependent
BACE1 increase. We transiently transfected HEK293 cells with
CMV promoter-driven expression vectors encoding BACE1
either with (+50UTR) or without (50UTR) the BACE1 50UTR (Lam-
mich et al., 2004) and then treated cultures in normal or NG
media for 24 hr (Figures 1G and 1H). Similar to our BACE1-293
cell experiments, transfection with the BACE1 +50UTR construct
followed by BACE1 immunoblot analysis revealed a 150%
increase of BACE1 levels when cells were incubated in NG
media, compared with control glucose-containing media (Fig-
ures 1G and 1H, left). Removal of the BACE1 50UTR caused an
increase in BACE1 levels in transfected cells (Figures 1G and
1H, right), as previously reported (Lammich et al., 2004). In addi-
tion to the mature 70 kDa BACE1 species, a significant propor-
tion of the BACE1 in cells transfected with the BACE1 50UTR
construct migrated at 60 kDa on immunoblots. Because the
60 kDa BACE1 species also labeled with an anti-BACE1
C-terminal antibody (data not shown), it was full-length BACE1
rather than a truncated BACE1 fragment and therefore was likely
to be immaturely glycosylated BACE1 (Haniu et al., 2000).
Apparently, the increased expression of BACE1 from the
BACE1 50UTR construct overloaded the ER, causing accumu-
lation of immature BACE1. Importantly, transfection with the
BACE150UTR construct followed by glucose deprivation failed
to cause BACE1 levels to increase above those observed in
BACE1 50UTR transfected cells incubated in glucose-contain-
ing media (Figures 1G and 1H, right). As expected, glucose
deprivation did not affect levels of BACE1 mRNA transcribed
from BACE1 +50UTR and 50UTR expression vectors, as
measured by TaqMan real-time PCR analysis (not shown).
Although unlikely, at this point we cannot exclude the possibility
that the glucose-deprivation-induced BACE1 increase was
masked by the large rise in BACE1 expression from the BACE150UTR construct. However, our results strongly suggest that
the BACE1 mRNA 50 UTR is necessary for the energy-depriva-
tion-dependent increase of BACE1 and further indicate that
a translational control mechanism is at play.
Energy Deprivation Increases eIF2a Phosphorylation
Control of translation initiation is considered to be of prime
importance for translational regulation. It is well established
that diverse cellular stresses affect translation at the level of initi-
ation (Clemens, 2001). Because our experiments demonstrated
that the BACE1 mRNA 50 UTR was required for the energy-depri-
vation-induced BACE1 increase, and that the BACE1 50UTR
exhibited characteristics of translationally regulated stress
response mRNAs, we investigated whether BACE1 levels might
be regulated by stress-induced translational control pathways
during energy deprivation. Initially, we screened cell lysates
from NG-treated and control BACE1-293 cells by immunoblot
for phosphorylation of proteins involved in translational regula-
tion after stress (Figures 2 and S1). Using this screen, we found
that phosphorylation of serine 51 of the a subunit of eukaryotic
translation initiation factor 2, eIF2a-P(Ser51), was dramatically
increased in response to NG treatment, implicating this compo-
nent of the translation initiation complex in the energy-depriva-
tion-induced BACE1 elevation. Strikingly, 24 hr of NG treatment
increased the ratio of eIF2a-P(Ser51) to total eIF2a (eIF2a-T) to
250% of cells grown in normal glucose-containing media
(Figures 2A and 2B; p < 0.01). Notably, eIF2a-P levels were
increased to 200% of control at only 2 hr of NG treatment,
a time when BACE1 levels had just begun to rise but were not
yet significantly elevated. Therefore, NG-induced eIF2a phos-
phorylation preceded the BACE1 increase, as expected for
a cause-and-effect relationship.
We found no evidence of alterations in the phosphorylation
state of the other major factor that is involved in the control of
translation initiation during stress, phosphorylated eukaryotic
translation initiation factor 4E (eIF4E-P; Figures 2A and 2B), indi-
cating that energy deprivation specifically increases phosphory-
lation of eIF2a. In addition, treatment of BACE1-293 cells with
rapamycin, an inhibitor of the serine/threonine kinase mamma-
lian target of rapamycin (mTOR), had no effect on BACE1 levels
(Figure S1). mTOR is the kinase that regulates eIF4E binding
protein (4E-BP), eukaryotic elongation factor 2 (eEF2) kinase,
and the ribosomal subunit protein S6 kinase. S6 and eEF2 are
in turn phosphorylated and regulated by S6 kinase and eEF2
kinase, respectively. Therefore, the negative rapamycin results
further exclude a role for eIF4E and indicate lack of involvement
of eEF2 and S6 in translational control of BACE1.
We also found no evidence of caspase-3 activation in glucose-
deprived BACE1-293 cells, indicating that apoptosis is not
involved in the BACE1 increase (Figure S2). We did observe
increased phosphorylation of the stress-activated proteins
c-Jun and c-Jun N-terminal kinase (JNK) in response to glucose
deprivation (Figures 2A and 2B), which might simultaneously
lead to transcriptional activation of other stress response
proteins. Interestingly, we also observed increased levels of total
c-Jun protein, the structural and functional homolog of the yeast
protein GCN4 (Struhl, 1987; Vogt et al., 1987), which is a well-
established translational target of the eIF2a-P pathway (FiguresNeuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 991
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Although it is unknown whether eIF2a-P regulates translation
of c-Jun mRNA, several studies report that c-Jun mRNA transla-
tion is increased under different conditions of stress or injury
(Gietzen et al., 2004; Polak et al., 2006; Rao, 2000; Spruill
et al., 2008; Vardimon et al., 2006). Taken together, these results
demonstrate that eIF2a phosphorylation is specifically increased
as a result of energy deprivation and is correlated with the
BACE1 increase.
Selective Inhibition of eIF2a Dephosphorylation
Increases BACE1 Levels
Phosphorylation of eIF2a on serine 51 is a major mechanism that
regulates initiation of translation in response to various cellular
stresses, including virus infection, nutrient deprivation, iron defi-
ciency, and accumulation of unfolded proteins in the ER (Clem-
ens, 2001; Proud, 2001). Depending on the specific cellular
stress, eIF2a is phosphorylated by at least 4 different kinases,
Figure 2. Glucose Deprivation Increases
eIF2a Phosphorylation and Activates
a Specific Set of Stress-Response Signaling
Pathways in BACE1-293 Cells
(A) BACE1-293 cells were incubated for 2 or 24 hr
in either normal DMEM with glucose (4500 mg/l;
CON) or DMEM without glucose (NG; n = 3 wells
per group). Cells were lysed and 10 mg total protein
per lane was used for immunoblot analysis of
BACE1, phospho-eIF2a(Ser51), total eIF2a,
phospho-c-Jun(Ser63), total c-Jun, phospho-
JNK(Thr183/Thr185), total JNK (54 kDa and
46 kDa isoforms), phospho-eIF4E(Ser209), and
b-actin (see Supplemental Experimental Proce-
dures for a list of antibodies used). Approximately
10 mg lysate from UV-treated 293 cells was used
as a positive control (+) for induction of stress-
response pathways.
(B) Immunosignals in (A) were quantified by phos-
phorimager and normalized in the following ways:
BACE1, eIF2a, JNK, and eIF4E-P were normalized
to b-actin; eIF2a-P was normalized to total eIF2a;
c-Jun-P was normalized to c-Jun; and JNK-P was
normalized to JNK. Values are expressed as
percentage of control (CON) for each time-point
(error bars indicate SEM). After 2 hr of NG treat-
ment, eIF2a-P, c-Jun-P, JNK-P (46 kDa), and
JNK (46 kDa) were all significantly elevated. At
24 hr NG, eIF2a-P, c-Jun-P, and JNK-P (46 kDa)
remained elevated, and BACE1, c-Jun, and
JNK-P (54 kDa) became significantly increased
as well. eIF4E phosphorylation was unaffected
by NG treatments at either time point. These
results show that eIF2a-P is temporally increased
before BACE1, as expected if eIF2a-P regulates
BACE1 translation (mean ± SEM; *p < 0.05; **p <
0.01; ***p < 0.001).
including double-stranded RNA-acti-
vated kinase (PKR), general control non-
derepressible 2 kinase (GCN2), heme-
regulated inhibitor kinase (HRI), and
PKR-like ER kinase (PERK). After stress-
induced phosphorylation of eIF2a, translation of normal cellular
mRNAs is repressed, whereas the translational initiation of select
mRNAs involved in stress response is stimulated. eIF2a-P is de-
phosphorylated by protein phosphatase-1 (PP1) complexed with
its regulatory subunit, growth arrest and DNA damage-inducible
protein 34 (GADD34). Importantly, the PP1/GADD34 complex is
inhibited by the small-molecule drug salubrinal (Sal), which
selectively blocks dephosphorylation of eIF2a-P but not other
PP1 substrates (Boyce et al., 2005).
If eIF2a phosphorylation stimulates the translation of BACE1
mRNA, then directly raising levels of eIF2a-P by selective inhibi-
tion of eIF2a-P dephosphorylation with Sal should increase
BACE1 levels in the absence of energy deprivation. To test this
hypothesis, we treated BACE1-293 cells for 24 hr with Sal
(100 mM), NG medium, or glucose-containing medium. Like NG
treatment, incubating BACE1-293 cells with Sal caused both
eIF2a-P(Ser51) and BACE1 levels to increase to 150%–200%
of control values (Figures 3A and 3B; p < 0.05). Therefore,992 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.
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Phosphorylation Affects the BACE1
Increase in BACE1-293 Cells
(A) BACE1-293 cells were incubated for 24 hr in
normal DMEM with glucose (25 mM; CON),
DMEM without glucose (NG), or DMEM containing
100 mM salubrinal (SAL). Cell lysates were
prepared and 10 mg total protein per lane was
used for immunoblot analysis of phosphorylated
eIF2a and total eIF2a. A parallel immunoblot was
prepared with 5 mg cell lysate per lane for analysis
of BACE1 and b-actin. The arrow identifies the
authentic eIF2a-P band (the upper band is
nonspecific).
(B) Immunosignals in (A) were quantified by phos-
phorimager, normalized, and expressed as
percentage of control (CON). BACE1 immunosig-
nals were normalized to b-actin, and eIF2a-P
was normalized to total (T) eIF2a. Levels of
BACE1 and eIF2a-P/eIF2a-T were significantly
elevated in response to both glucose deprivation
and Sal treatment, compared with control (mean ±
SEM; *p < 0.05; ***p < 0.001; n = 2 per group).
Note that Sal treatment caused direct increases
of eIF2a-P and BACE1 levels in the absence of
glucose deprivation. These Sal-induced increases
were similar in size to those caused by no-glucose
treatment.
(C) BACE1-293 cells were transiently transfected
with GADD34 control vector (CON, 12h NG) or
GADD34DN (NG + GADD34DN), the constitutively
active PP1 regulatory subunit. After overnight
recovery, cells were incubated for 12 hr in normal
DMEM with glucose (CON) or DMEM without
glucose (12h NG, NG + GADD34DN). Cell lysates
were prepared and 10 mg total protein per lane
was used for immunoblot analysis of BACE1,
P-eIF2a(Ser51), total eIF2a, and b-actin. ‘‘+’’
lane: 10 mg lysate from UV-treated 293 cells was
used as a positive control for eIF2a-P.
(D) Immunosignals in (C) were quantified by phos-
phorimager, normalized, and expressed as
percentage of control (CON). BACE1 immunosig-
nals were normalized to b-actin, and eIF2a-P
was normalized to total eIF2a. Glucose-depriva-
tion-induced increases in levels of BACE1 and
eIF2a-P/eIF2a-T were completely prevented by
overexpression of GADD34DN, demonstrating that eIF2a phosphorylation was responsible for the BACE1 increase (n = 4; comparison between CON and
12h NG: *p < 0.05; ***p < 0.001; comparison between 12h NG and NG + GADD34DN: ##p < 0.01; ###p < 0.001; mean ± SEM).
(E) BACE1-293 cells were transiently transfected with pcDNA3 empty vector (CON, NG) or dominant-negative PERK (PERKDN). After overnight recovery, cells
were incubated for 24 hr in normal DMEM with glucose (CON) or DMEM without glucose (NG, NG + PERKDN). Cell lysates were prepared and 10 mg total protein
per lane was used for immunoblot analysis of phosphorylated eIF2a and total eIF2a. A parallel immunoblot was prepared with 5mg cell lysate per lane for immu-
noblot analysis of BACE1 and b-actin.
(F) BACE1 immunosignals in (E) were quantified by phosphorimager and expressed as percentage of control (CON). Glucose-deprivation-induced increases in
BACE1 levels were completely prevented by overexpression of PERKDN, demonstrating that PERK was the eIF2a kinase responsible for eIF2a phosphorylation
and the BACE1 increase (n = 3 per group; **, comparison between CON and NG, p < 0.01; #, comparison between NG and NG + PERKDN, p < 0.05; mean ± SEM).
(G) BACE1-293 cells were transiently transfected with pcDNA3 empty vector (CON, NG) or dominant-negative GCN2 (GCN2DN). After overnight recovery, cells
were incubated for 24 hr in normal DMEM with glucose (CON) or DMEM without glucose (NG, NG + GCN2DN). Cell lysates were prepared and 10 mg total protein
per lane was used for immunoblot analysis of phosphorylated eIF2a and total eIF2a. A parallel immunoblot was prepared with 5mg cell lysate per lane for
immunoblot analysis of BACE1 and b-actin.
(H) BACE1 immunosignals in (G) were quantified by phosphorimager and expressed as percentage of control (CON). The glucose-deprivation-induced increase in
BACE1 level was not prevented by overexpression of GCN2DN, demonstrating that GCN2 was not the eIF2a kinase responsible for eIF2a phosphorylation and
the BACE1 increase (n = 3 per group; *, comparison between CON and NG, p < 0.05; mean ± SEM). Error bars represent SEM in all histograms.Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 993
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caused the BACE1 increase without the need of glucose depri-
vation, demonstrating that BACE1 is a translational target of
the stress-activated eIF2a-P(Ser51) pathway.
Blocking eIF2a Phosphorylation by Constitutive
Activation of the PP1/GADD43 Complex Prevents
the Energy-Deprivation-Induced BACE1 Increase
To further establish the role of eIF2a in BACE1 translational
control, we sought to determine the effects of directly blocking
eIF2a phosphorylation on the energy-deprivation-induced
BACE1 increase. For this we used a construct encoding only
the C-terminal activation domain of GADD34 that lacks the
N-terminal regulatory domain (GADD34DN) and thus constitu-
tively activates PP1 (Novoa et al., 2001). Therefore,upon transfec-
tion GADD34DN should prevent the increases of both eIF2a-P
and BACE1 after glucose deprivation. To test this, we transiently
transfected BACE1-293 cells with expression constructs encod-
ing either GADD34DN or an inactive GADD34 construct lacking
the C-terminal PP1 activation domain, which has no effect on
PP1 activity and served as a transfection control. After overnight
recovery, GADD34DN and control-transfected cells were treated
for 12 hr in NG or glucose-containing media, and cell lysates were
analyzed by immunoblot for BACE1 and eIF2a-P. Control-trans-
fected BACE1-293 cells exhibited the expected increase in levels
of BACE1 and eIF2a-P(Ser51) levels in response to NG treatment
(Figure 3C, middle four lanes; Figure 3D). In contrast, GADD34DN-
transfected cells incubated in NG media showed no increase in
eIF2a-P(Ser51) or BACE1 levels in response to NG treatment
(Figure 3C, right four lanes; Figure 3D) compared with control
transfection, demonstrating that inhibition of eIF2a phosphoryla-
tion completely blocks NG-induced BACE1 elevation. Together
with our Sal experiments, these results clearly demonstrate that
the rise in BACE1 level in response to energy deprivation is the
result of increased phosphorylation of eIF2a at Ser51.
Activation of the eIF2a Kinase PERK Is Necessary
for the Energy-Deprivation-Induced BACE1 Increase
Of the four known eIF2a kinases, the two most likely to be
induced by energy metabolism stress are PERK and GCN2,
which are activated by the ER stress/unfolded protein response
(UPR) and amino acid deprivation, respectively. PKR and HRI are
less likely to play a role in the energy-deprivation-induced
BACE1 increase because they are activated by virus infection
and heme deficiency in erythrocytes, respectively (Clemens,
2001). Therefore, we sought to determine whether PERK or
GCN2 was responsible for phosphorylating eIF2a and causing
the BACE1 increase after glucose deprivation. To accomplish
this, we used kinase-dead forms of PERK and GCN2 that had
a C-terminal deletion (PERK; Harding et al., 1999) or were
mutated at the critical lysine 618 residue in the conserved kinase
domain of the enzyme (GCN2; Sood et al., 2000), thus producing
dominant-negative molecules that block eIF2a phosphorylation.
We transiently transfected BACE1-293 cells with constructs
encoding dominant-negative PERK (PERKDN) or GCN2
(GCN2DN), allowed cells to recover overnight, and then treated
cells for 12 hr in NG or glucose-containing media. Expression
of GCN2DN in combination with glucose deprivation failed to994 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.prevent eIF2a phosphorylation or BACE1 elevation in BACE1-
293 cells (Figures 3G and 3H), indicating that GCN2 is not the
kinase that phosphorylates eIF2a under glucose-deficient condi-
tions. In contrast, expression of PERKDN in combination with NG
treatment completely blocked the increases of both eIF2a-P and
BACE1 (Figures 3E and 3F), demonstrating that PERK is the
specific kinase responsible for phosphorylating eIF2a and
controlling the energy-deprivation-induced BACE1 elevation.
To provide further support for the role of PERK in BACE1 trans-
lational control, we performed two additional experiments using
a cellular inhibitor of PERK, P58IPK (Yan et al., 2002), and the
compound tauroursodeoxycholic acid (TUDCA), which alleviates
ER stress (Ozcan et al., 2006). The unfolded protein/ER stress
response induces the expression of P58IPK, a molecular chap-
erone that is thought to bind to the kinase domain of PERK
and inhibit its activity (Yan et al., 2002). Transient transfection
of BACE1-293 cells with an expression vector encoding P58IPK
prevented the BACE1 increase after glucose deprivation (Figures
S3A and S3B), mirroring our previous results with PERKDN
transfection. Similarly, TUDCA treatment of BACE1-293 cells
also blocked the BACE1 increase caused by incubation in NG
medium (Figures S3C and S3D). Taken together, our experi-
ments with PERKDN, GCN2DN, P58IPK, and TUDCA strongly
suggest that PERK is the eIF2a kinase activated by energy depri-
vation, and that it is ultimately responsible for the eIF2a-
P-induced translational increase of BACE1.
Glucose Deprivation Causes eIF2a Phosphorylation
and Increases BACE1 Levels in Cultured Primary
Neurons by a Posttranscriptional Mechanism
Thus far in our analysis, we had demonstrated that PERK and
phosphorylation ofeIF2awere responsible for the energy-depriva-
tion-induced BACE1 increase in BACE1 overexpressing HEK293
cells. We next wanted to show that the same translational control
mechanism was involved in the regulation of endogenous BACE1
in neurons. To accomplish this, we cultured C57/BL6 mouse
primary cortical neurons for 7 days in vitro (DIV) and then treated
cultures for up to 48 hr in NG or glucose-containing media. Neuron
lysates were prepared and analyzed for endogenous BACE1
levels by immunoblot. BACE1 levels were increased in primary
neuron cultures by 24 hr of treatment in NG media (not shown)
and peaked at 36 hr (Figures 4A and 4B; 150% of control,
p < 0.05). Unexpectedly, TaqMan quantitative PCR analysis of
mRNA isolated from parallel primary neuron cultures showed
a decrease in BACE1 transcript levels in response to NG media
(Figure 4C; p < 0.05), clearly demonstrating that a posttranscrip-
tional mechanism was responsible for the BACE1 increase after
NG treatment. Similar to BACE1-293 cells, the eIF2a-P(Ser51):
eIF2a total ratio in 36 hr NG-treated primary neurons was elevated
to150% of control values (Figures 4A and 4B; p < 0.05) indicating
that eIF2a phosphorylation was the likely mechanism of the
BACE1 protein elevation in neurons as well.
Selective Inhibition of eIF2a Dephosphorylation
Increases BACE1 Level and Ab Production in Tg2576
Primary Neurons
If eIF2a phosphorylation increases the translation of BACE1
mRNA in neurons as it does in BACE1-293 cells, then directly
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Phosphorylated eIF2a Increases BACE1 and Ab LevelsFigure 4. eIF2a Phosphorylation Causes Posttranscriptional Increases of BACE1 and Promotes Ab Production in Cultured Primary Neurons
(A) Primary cortical C57/BL6 neurons were cultured for 7 DIV and then incubated for 36 hr in media containing 20 mM glucose (CON) or no glucose (NG). Cell
lysates were prepared and 10 mg total protein per lane was used for immunoblot analysis of BACE1, P-eIF2a(Ser51), total eIF2a (eIF2a-T), and b-actin.
(B) Immunosignals in (A) were quantified by phosphorimager, normalized, and expressed as percentage of control (CON). BACE1 immunosignals were normal-
ized to b-actin, and eIF2a-P was normalized to eIF2a-T. Levels of endogenous neuronal BACE1 and eIF2a-P/eIF2a-T were significantly elevated in response to
glucose deprivation (mean ± SEM; *p < 0.05; n = 3), and the sizes of the increases were similar to those observed in BACE1-293 cells.
(C) Parallel C57/BL6 primary neuron cultures were treated as in (A), except that total mRNA was isolated and levels of endogenous BACE1 mRNA measured via
the TaqMan real-time PCR relative quantification method and expressed as percentage of control (CON; n = 3). Unexpectedly, neuronal BACE1 mRNA levels
were significantly reduced in cultures treated with NG-media compared with glucose-containing media (CON) (#; p < 0.05; mean ± SEM), clearly demonstrating
a posttranscriptional mechanism for the BACE1 protein increase.
(D) Primary cortical Tg2576 neurons were cultured for 7 DIV and then incubated for 48 hr in normal media with glucose (CON), glucose-containing media with
50 mM Sal, or glucose-containing media with 80 mM Sal. Cell lysates were prepared and 10 mg total protein per lane was used for immunoblot analysis of
BACE1, phosphorylated eIF2a, total eIF2a, and b-actin. Ten micrograms lysate from UV-treated 293 cells was used as a positive control (+) for eIF2a-P.
(E) Immunosignals in (D) were quantified by phosphorimager, normalized, and expressed as percentage of control (CON). BACE1 was normalized to b-actin, and
eIF2a-P was normalized to eIF2a-T. BACE1 levels and eIF2a-P/eIF2a-T ratios were significantly increased in Tg2576 neurons treated with both concentrations of
Sal compared with control (CON; n = 4; *p < 0.05; **p < 0.01; ***p < 0.001; mean ± SEM), demonstrating that direct induction of eIF2a phosphorylation causes
BACE1 levels to rise.
(F) Conditioned media collected from 48 hr Sal-treated Tg2576 neurons in (D) were analyzed using a human Ab40 ELISA. Values are expressed as nanograms of
Ab40 in the media per milligram of total protein in the corresponding cell lysate. Ab40 levels were significantly elevated in Tg2576 neurons treated with both 50 mM
and 80 mM Sal compared with control (CON; n = 4; *p < 0.05; **p < 0.01; mean ± SEM), demonstrating that direct induction of eIF2a phosphorylation led to an
increase in Ab production.raising levels of neuronal eIF2a-P by selective inhibition of
eIF2a-P dephosphorylation with Sal treatment should elevate
BACE1 levels in the absence of energy deprivation. Moreover,
the resulting rise in BACE1 level should cause an increase in
neuronal Ab generation as well. To test these hypotheses, we
cultured primary cortical neurons from Tg2576 transgenic mice
that overexpress human APPsw (Hsiao et al., 1996) and treated
the cultures with Sal. Because the effects of Sal on primary
neurons had not yet been published, we chose two Sal concen-
trations (50 mM and 80 mM) that we determined from a previous
study (Boyce et al., 2005) would be likely to inhibit PP1/GADD34
with minimal neuronal toxicity. Tg2576 primary neurons from
E15.5 embryos were cultured for 7 DIV, treated with 50 mM or
80 mM Sal for 48 hr, and conditioned media and neuronal lysates
collected. As we observed in BACE1-293 cells, immunoblot
analysis revealed that Sal treatment increased levels of botheIF2a-P(Ser51) and endogenous BACE1 protein in Tg2576
neurons (Figures 4D and 4E). Furthermore, these results together
with the glucose deprivation experiments establish that the same
mechanism of BACE1 increase occurs in both BACE1-293 cells
and primary neurons.
Next, we determined whether Sal treatment of the Tg2576
neuron cultures had increased Ab production. To do so, we
used a human Ab40-specific ELISA to measure levels of the 40-
amino-acid isoform of Ab (Ab40) secreted into the conditioned
media of control, 50 mM, and 80 mM Sal-treated neuron cultures.
Changes in BACE1 activity affect the generation of all isoforms of
Ab equally (Vassar et al., 1999). Ab40 is the most abundant Ab
isoform produced in cells and tissues, and it is a gauge of
BACE1 activity in cells. In addition, Ab40 is the major isoform of
Ab produced in Tg2576 transgenic mice. As expected, Ab40
levels were significantly elevated in conditioned media fromNeuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 995
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CON = 13.25 ± 0.33 ng Ab40/mg protein; 50 mM Sal = 15.88 ±
0.63, p < 0.05; 80 mM Sal = 27.19 ± 1.61, p < 0.01).
The Ab40 increase for the 50 mM Sal-treated Tg2576 neurons
was less than expected, based on the level of phosphorylated
eIF2a (Figures 4E and 4F). The reason for this is unclear, but
we suspect that BACE1 levels increased at a slower rate in
50 mM Sal compared with 80 mM Sal, thereby delaying the Ab40
increase. It is likely that Ab40 levels in 50 mM Sal treated cultures
would have eventually caught up with those of 80 mM Sal.
Regardless, it is important to note that the Ab40 increase in
50 mM Sal-treated Tg2576 neurons was significant, and that
the Ab40 increase for 80 mM Sal was2-fold over control. In addi-
tion, our results demonstrate that selective inhibition of eIF2a
dephosphorylation directly causes BACE1 levels to increase in
neurons in the absence of energy deprivation. Taken together,
the Sal-treated Tg2576 neuron cultures confirm that BACE1 is
a translational target of eIF2a-P(Ser51) in neurons and demon-
strate that direct induction of eIF2a-P increases Ab production,
which has important implications for AD pathogenesis.
Chronic Energy Inhibition Increases eIF2a
Phosphorylation, BACE1 Levels, and Amyloidogenesis
in Tg2576 Mice
Thus far, our results demonstrated that energy deprivation
caused increases in eIF2a phosphorylation, BACE1 translation,
and Ab production in vitro, conditions that we predicted would
exacerbate amyloid deposition in vivo. To test this, we designed
a chronic in vivo energy deprivation paradigm based on our
previous acute study in which we treated Tg2576 mice with
inhibitors of energy metabolism that caused increases in
BACE1 level and Ab production (Velliquette et al., 2005). In that
acute study, we gave 2-month-old Tg2576 mice single intraper-
itoneal (i.p.) injections of compounds that produced or mimicked
hypoglycemia, inhibited ATP synthesis, or caused neuronal
overexcitation that depleted ATP stores: insulin, 2-deoxyglucose
(2DG) and 3-nitropropionic acid (3NP), and kainic acid (KA).
Because our in vitro studies primarily focused on the effects of
glucose deprivation on eIF2a phosphorylation and BACE1 level
elevation, in the chronic in vivo study we chose to only use the
two compounds that would specifically interfere with glucose
energy metabolism at the level of glycolysis and the Krebs cycle:
2DG and 3NP. 2DG is a glucose analog that is a competitive
inhibitor of hexokinase, whereas 3NP inhibits the Krebs cycle
and electron transport chain enzyme succinate dehydrogenase.
Insulin and KA were not used in the current study because we
reasoned that these two compounds were more likely to cause
pleiotropic physiological effects in vivo, especially under condi-
tions of chronic dosing, thus potentially complicating the inter-
pretation of results.
For our chronic in vivo energy deprivation experiment,
9-month-old Tg2576 and C57/BL6 (wild-type) mice were treated
once per week with i.p. injections of 2DG (1 g/kg), 3NP (80 mg/kg),
or vehicle for a duration of 3 months. In our acute study, BACE1
and Ab levels stayed elevated for at least a week after a single
dose of 2DG or 3NP (Velliquette et al., 2005), thus providing
the rationale for single weekly injections in the current study.
Treatments were started at 9 months of age, when Tg2576996 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.mice were on the cusp of amyloid plaque formation (Hsiao
et al., 1996), and concluded when mice were 12 months old.
The doses of 2DG and 3NP were chosen based on a pilot study
showing that they were able to increase BACE1 to levels similar
to those observed in our acute study (not shown). These doses
were well-tolerated by the mice, no mortality was observed,
and treatments caused only temporary lethargy lasting 30–
60 min. Cresyl violet staining and GFAP immunohistochemistry
of brain sections from 2DG- or 3NP-treated mice revealed no
significant neurodegeneration or gliosis associated with treat-
ment (Figure S4).
After 3 months of treatment, hemibrains of each Tg2576
mouse were analyzed for levels of eIF2a-P, BACE1 (by immuno-
blot) and Ab40 (ELISA), and amyloid plaque number (by anti-Ab
immunohistochemistry and Thioflavin-S staining). C57/BL6
hemibrains were analyzed in a similar manner as those of
Tg2576, except one hemibrain from each C57/BL6 mouse was
processed for TaqMan mRNA quantification rather than
histology. As expected, chronic experimental glucose depriva-
tion caused a significant increase of BACE1 level in the brains
of Tg2576 (Figures 5A and 5C) and C57/BL6 (Figures 6A and
6B) mice. 2DG and 3NP-treated mice exhibited BACE1
increases of 120%–130% (p < 0.05) and 160%–170% (p <
0.001), respectively, in comparison to vehicle control treatment.
Importantly, the BACE1 increases after chronic treatment were
similar in magnitude to those observed under conditions of acute
energy deprivation in vivo (Velliquette et al., 2005) and in vitro
(this study).
Based on our in vitro studies with BACE1-293 cells and
primary neurons, we predicted that the BACE1 increase after
chronic in vivo energy deprivation would be posttranscriptional.
To test this, we isolated mRNA from hemibrains of C57/BL6 mice
chronically treated with 2DG, 3NP, and vehicle and measured
levels of endogenous mouse BACE1 mRNA by TaqMan quanti-
tative real-time PCR analysis. Indeed, BACE1 mRNA levels were
not increased upon 2DG or 3NP treatment, and in fact were
significantly decreased compared with vehicle (Figure 6C).
Although we do not fully understand the reason for this mRNA
decrease, we speculate that it might be a result of global down-
regulation of transcription caused by ATP depletion. In any case,
our results clearly demonstrate that the BACE1 elevations in
response to chronic in vivo energy deprivation were not the result
of either increased BACE1 gene transcription or enhanced
BACE1 mRNA stabilization.
Because our previous results showed that eIF2a phosphoryla-
tion and enhanced BACE1 translation were responsible for the
energy-deprivation-induced BACE1 increase in vitro, we wanted
to determine whether increased eIF2a phosphorylation might
account for the BACE1 elevation in vivo. To accomplish this,
we used immunoblot analysis to measure phosphorylated and
total eIF2a levels in brain homogenates of Tg2576 mice treated
with 2DG, 3NP, or vehicle (Figures 5B and 5C). The eIF2a-
P(Ser51):eIF2a-T ratios in the brains of 2DG- and 3NP-treated
mice were elevated to 130% (p < 0.05) and 150% (p < 0.01)
of vehicle, respectively (Figure 5C), similar to the increases in
eIF2a phosphorylation observed in vitro. Importantly, mean
increases in eIF2a phosphorylation correlated with the BACE1
elevations that occurred in 2DG- and 3NP-treated mice. These
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Phosphorylated eIF2a Increases BACE1 and Ab Levelsresults, together with our in vitro BACE1-293 cell and primary
neuron data, suggest that chronic energy deprivation in vivo
induces the eIF2a translational control pathway, thereby
increasing BACE1 levels.
Previous studies had reported that modest overexpression of
BACE1 increased Ab levels and amyloid deposition in trans-
genic mice (Bodendorf et al., 2002; Chiocco et al., 2004;
Chiocco and Lamb, 2007; Lee et al., 2005; Mohajeri et al.,
2004; Ozmen et al., 2005; Willem et al., 2004). Therefore, the
elevated BACE1 levels in 2DG and 3NP-treated Tg2576 mice
suggested that levels of Ab and amyloid plaques might also
be increased in these animals. To investigate this, we measured
Ab40 in brain homogenates by Ab40-specific ELISA and counted
amyloid plaques in hemibrain sections from treated Tg2576
mice. 2DG and 3NP treatment caused clear trends toward
increased Ab40 levels (Figure 5D; VEH = 9.10 ± 1.30 ng Ab40/mg
protein, 2DG = 13.15 ± 1.94, 3NP = 15.56 ± 3.75) and plaque
numbers (Figures 5E; VEH = 20.8 ± 3.7; 2DG = 26.7 ± 5.3;
3NP = 36.0 ± 8.6), with a nearly 2-fold increase occurring in
3NP-treated mice. Consistent with these observations, exami-
nation of brain sections stained with anti-Ab antibody (Figures
5F and S5) or Thioflavin-S (Figure S5) showed that plaques in
2DG- and 3NP-treated mice appeared larger and more
numerous than in vehicle-treated mice. High interanimal vari-
ability in treated mice caused the increases of Ab40 level and
plaque number to not quite reach statistical significance,
although it is likely that statistical significance would have
been achieved with longer treatment times.
Figure 5. Elevated BACE1 Levels Are Corre-
lated with Increased eIF2a-P and Amyloido-
genesis in a Chronic Model of Energy
Deprivation In Vivo
(A) Nine-month-old Tg2576 mice were adminis-
tered i.p. injections of saline (VEH), 1 g/kg 2-deox-
yglucose (2DG), or 80 mg/kg 3-nitropropionic acid
(3NP) once a week for 3 months (8 or 9 mice per
group). One week after the final injection, hemi-
brains from each mouse were harvested and
prepared for immunoblot and immunohistochem-
ical analyses. Brain homogenates were prepared
and 10 mg total protein per lane were used for
immunoblot analysis of total BACE1 protein and
b-actin. ‘‘+’’ lane: 5 mg BACE1-293 cell lysate as
a BACE1 positive control; ‘‘’’ lane: 10 mg
BACE1/ mouse brain homogenate as a BACE1
negative control.
(B) Fifteen micrograms total protein per lane of
brain homogenate from VEH-, 2DG-, and 3NP-
treated Tg2576 mice were used for immunoblot
analysis of eIF2a-P, eIF2a-T, and b-actin. ‘‘+’’
lane: 10 mg lysate from UV-treated 293 cells as
a positive control for eIF2a-P.
(C) Immunosignals in (A) and (B) were quantified by
phosphorimager and expressed as percentage of
vehicle (VEH). BACE1 levels and eIF2a-P/eIF2a-T
ratios were significantly elevated in 2DG- and
3NP-treated Tg2576 mice compared with VEH
(mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001).
(D) Guanidine-extracted brain homogenates from
VEH-, 2DG-, and 3NP-treated Tg2576 mice were
analyzed using a human Ab40 ELISA. Values
were expressed as nanograms of Ab40 per milli-
gram of total protein. A clear trend toward eleva-
tion of Ab40 level was observed in 2DG- and
3NP-treated mice, although values did not reach
statistical significance. Increases in Ab40 levels
tended to parallel the elevations of eIF2a-P and
BACE1 for 2DG and 3NP treatments (compare C
and D).
(E) Fixed hemibrains of each mouse treated with
VEH, 2DG, and 3NP were sectioned and stained
with anti-Ab antibody 4G8. The total number of 4G8-immunopositive plaques was counted in a set of eight evenly spaced parasagittal sections that spanned
the entire medial-lateral dimension of each hemibrain. A clear trend toward an increase in plaque number was observed for both 2DG and 3NP treatments
compared with VEH. Plaque numbers for the different treatments paralleled the relative levels of Ab40, as expected (compare with 5D), as well as the levels of
eIF2a-P and BACE1 (compare with 5C).
(F) Representative parasagittal brain sections from VEH-, 2DG-, and 3NP-treated Tg2576 mice were immunostained with 4G8 and micrographed at 43. 4G8-
positive plaques in the brains of 2DG- and 3NP-treated mice tended to be larger and more numerous than those in VEH treated mice.Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 997
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always produced the strongest increases of phosphorylated
eIF2a, BACE1, Ab40, and plaque number, whereas 2DG treat-
ment always had more moderate effects (compare Figures 5C–
5E). 3NP is a strong, irreversible inhibitor of glucose metabolism,
in contrast to the weaker reversible inhibitor, 2DG. Thus, the
effects of the drugs on phosphorylated eIF2a, BACE1, Ab40,
and plaque number reflected their relative potency for inhibiting
glucose metabolism. Taken together, these observations make
a compelling case that chronic energy deprivation in vivo is likely
to promote amyloidogenesis via a mechanism involving eIF2a
phosphorylation and BACE1 translational control.
Finally, we wanted to exclude the possibility that other mech-
anisms were responsible for elevating BACE1 levels and
promoting amyloidogenesis in 2DG- and 3NP-treated Tg2576
mice, such as altered microRNA (miRNA) expression, increased
g-secretase, or decreased Ab degrading enzyme levels. Recent
studies have shown that miRNAs miR-29a, 29b-1, and 9 are
decreased in AD and are capable of regulating BACE1 expres-
sion in vitro (Hebert et al., 2008; Wang et al., 2008). Therefore,
we measured the levels of miR-29a, 29b-1, and 9 in treated
Tg2576 mice by TaqMan quantitative RT-PCR analysis. We
Figure 6. Chronic Energy Deprivation Causes Posttranscriptional
Increases of BACE1 In Vivo
(A) Nine-month-old wild-type C57/BL6 mice were administered i.p. injections
of saline (VEH), 1 g/kg 2-deoxyglucose (2DG), or 80 mg/kg 3-nitropropionic
acid (3NP) once a week for 3 months. One week after the final injection, hemi-
brains from each mouse were harvested and prepared for immunoblot and
TaqMan quantitative real-time PCR analyses. Brain homogenates were
prepared and 10 mg total protein per lane were used for immunoblot analysis
of BACE1, full-length APP, and b-actin. ‘‘+’’ lane: 5 mg of BACE1-293 cell lysate
as a BACE1 positive control; ‘‘’’ lane: 10 mg BACE1/ mouse brain homog-
enate as a BACE1 negative control.
(B) Immunosignals in (A) were quantified by phosphorimager and expressed as
percentage of vehicle (VEH; n = 4–6 per group). BACE1 levels were signifi-
cantly elevated in the brains of both 2DG- and 3NP-treated C57/BL6 mice
compared with VEH (mean ± SEM; *p < 0.05; ***p < 0.001).
(C) Total mRNA was isolated from the hemibrains of VEH-, 2DG-, and 3NP-
treated C57/BL6 mice and levels of endogenous BACE1 and APP mRNAs
measured via the TaqMan real-time PCR relative quantification method and
expressed as percentage of vehicle (VEH; 9–12 mice per group). Strikingly,
both BACE1 and APP mRNA levels were significantly decreased in 2DG-
and 3NP-treated C57/BL6 mice compared with VEH (mean ± SEM; **, p <
0.01; ***, p < 0.001).998 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.found that none of these miRNAs were decreased in brains sub-
jected to chronic energy deprivation (Figure S6). In fact, miR-29a
and 29b-1 were increased in 3NP-treated mice, as compared
with vehicle treatment, which would be expected to decrease
BACE1 levels (Hebert et al., 2008; Wang et al., 2008). Next, we
performed immunoblot analyses for the amino-terminal frag-
ment (NTF) of presenilin 1 (PS1), a critical subunit of the g-secre-
tase, and insulin degrading enzyme (IDE) and neprilysin (NEP),
two major Ab-degrading enzymes (Figure S7). Overall, the levels
of these molecules were not significantly affected by chronic
energy deprivation in vivo (Figures S7A and S7B), although
a trend toward elevated NEP levels was observed for 3NP-
treated mice, a condition that would be expected to decrease
Ab levels. In addition, PS1-NTF, IDE, and NEP levels were not
altered in Sal-treated Tg2576 primary neuron cultures (Figures
S7C and S7D). Taken together, these results make it unlikely
that miRNAs, g-secretase, or Ab-degrading enzymes played
a major role in the increased levels of BACE1 and Ab in response
to chronic energy deprivation in Tg2576 mice.
Increased eIF2a Phosphorylation Correlates
with Elevated BACE1 Levels in 5XFAD Transgenic
Mice and Humans with AD
At this point in our analysis, the in vitro and in vivo energy-depri-
vation experiments suggested the possibility that impaired
energy metabolism in AD could increase BACE1 levels via
a mechanism involving eIF2a phosphorylation and exacerbate
amyloidogenesis. Reports had already shown that BACE1 levels
and activity were increased in AD brains compared with nonde-
mented controls (Fukumoto et al., 2002; Holsinger et al., 2002; Li
et al., 2004; Sennvik et al., 2004; Tyler et al., 2002; Yang et al.,
2003). Moreover, we had demonstrated that BACE1 levels
were dramatically elevated around amyloid plaques in AD
patients, Tg2576 mice, and in our aggressive amyloid deposition
model, 5XFAD transgenic mice (Zhao et al., 2007). However, no
study had yet addressed whether chronic energy deprivation or
eIF2a phosphorylation was potentially involved with the BACE1
increase in AD. If impaired cerebral energy metabolism played
a role in sporadic AD, and if the mechanism entailed increased
translation of BACE1 as a result of eIF2a phosphorylation, then
we would expect to observe increased levels of eIF2a-P and
correlation between eIF2a-P and BACE1 levels in AD brain.
Similar conditions might also exist in APP transgenic mice,
because we observed a robust BACE1 increase in the brains
of 5XFAD transgenic mice (Zhao et al., 2007).
To initially test these hypotheses, we analyzed levels of
BACE1, eIF2a-P, and eIF2a-T by immunoblot in the brains of
6-month-old 5XFAD mice that had florid amyloid pathology
(Oakley et al., 2006). In agreement with our recent report (Zhao
et al., 2007), we observed that BACE1 levels in 5XFAD brains
were increased to 170% of nontransgenic (non-Tg) littermate
controls (p < 0.01; Figures 7A and 7B). As we had predicted,
levels of eIF2a-P(Ser51) were elevated in 5XFAD brain as well
(Figure 7A). Unexpectedly, however, total eIF2a levels were
also increased in 5XFAD brain compared with non-Tg control.
Importantly, despite the elevated eIF2a-T levels, the eIF2a-
P(Ser51):eIF2a-T ratio was significantly increased to 120% of
non-Tg control in 5XFAD brains (p < 0.05; Figures 7A and 7B).
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total eIF2a remains unclear; however, we speculate that it might
represent an adaptive response to chronic stress caused by the
aggressive amyloid deposition in 5XFAD mice. It is noteworthy
that increased BACE1 mRNA levels were not responsible for
the BACE1 elevation in 5XFAD mice (Zhao et al., 2007), thus sug-
gesting a posttranscriptional mechanism most likely involving
eIF2a phosphorylation. In addition, we measured levels of miR-
29a, 29b-1, and 9 and found no evidence that these miRNAs
had altered expression in 5XFAD brains (Figure S6). Finally, it is
significant that 5XFAD mice had elevated cerebral eIF2a-P and
BACE1 levels in the absence of pharmacologically induced
Figure 7. eIF2a-P Levels Are Elevated in 5XFAD Transgenic Mouse and Human AD Brains and Positively Correlate with BACE1 Levels and
Amyloid Loads
(A) Brain homogenates were prepared from 6-month-old 5XFAD transgenic (5XFAD) mice and nontransgenic littermates (Non-Tg), and 10 mg total protein per lane
was used for immunoblot analysis of BACE1, full-length APP (FLAPP), eIF2a-P, eIF2a-T, and b-actin. ‘‘+’’ lane: 10 mg of lysate from UV-treated 293 cells was used
as a positive control for eIF2a-P.
(B) Immunosignals in (A) were quantified by phosphorimager, normalized, and expressed as percentage of nontransgenic littermate levels. BACE1 and eIF2a-T
immunosignals were normalized to b-actin, and eIF2a-P was normalized to eIF2a-T. ‘‘’’: non-transgenic littermates; ‘‘+’’: 5XFAD transgenic mice. BACE1 levels
and eIF2a-P/eIF2a-T ratios were significantly elevated in 5XFAD mice compared with Non-Tg (n = 5 mice/group; *p < 0.05; **p < 0.01; mean ± SEM).
(C) Human postmortem frontal cortex samples from AD patients (AD) and age-matched nondemented controls (N) were homogenized and prepared for immu-
noblot analysis as described in Experimental Procedures. Fifteen micrograms total protein per lane was analyzed by immunoblot for BACE1, eIF2a-P, eIF2a-T,
and b-actin; 10 mg lysate from UV-treated 293 cells was used as a positive control for eIF2a-P (+).
(D) Immunosignals in (C) were quantified by phosphorimager, normalized, and expressed as percentage of nondemented (ND) control. BACE1 and eIF2a-T
immunosignals were normalized to b-actin, and eIF2a-P was normalized to eIF2a-T. Both BACE1 level and eIF2a-P/eIF2a-T ratio were significantly elevated
in AD brains compared with ND (n = 9 AD, 13 ND; *p < 0.05; **p < 0.01; mean ± SEM).
(E–G) BACE1 levels and eIF2a-P/eIF2a-T ratios determined in (D) and amyloid loads (% area; see Experimental Procedures) were correlated by linear regression
analyses of BACE1 level versus eIF2a-P/eIF2a-T ratio (E), amyloid load versus eIF2a-P/eIF2a-T ratio (F), and amyloid load versus BACE1 level (G) for individual AD
and ND frontal cortex samples. Amyloid load was expressed as the average percent area of AD or ND frontal cortex section occupied by plaques immunostained
with total anti-Ab antibody. Statistically significant correlations were found for BACE1 level versus eIF2a-P/eIF2a-T ratio (p < 0.05), amyloid load versus eIF2a-P/
eIF2a-T ratio (p < 0.01), and amyloid load versus BACE1 level (p < 0.05).Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 999
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Phosphorylated eIF2a Increases BACE1 and Ab Levelsenergy deprivation, indicating that eIF2a phosphorylation could
be increased by amyloid pathology as well as energy depriva-
tion. This has important implications for a potential positive feed-
back mechanism that might drive BACE1 elevation and amyloi-
dogenesis in AD (Figure 8).
As the final step in our study, it was necessary to verify that
eIF2a phosphorylation and BACE1 were elevated in AD brain.
To accomplish this, we performed immunoblot analysis to
measure levels of BACE1, eIF2a-P, and eIF2a-T in a series of
cortical human brain samples from AD patients and age-
matched, nondemented (N) controls (Figures 7C and 7D). In
agreement with previous reports, BACE1 levels were signifi-
cantly elevated in AD brains (140% of N control; p < 0.01). As
predicted, AD brains also exhibited increased eIF2a-P(Ser51)
levels (Figure 7C, D), and the AD eIF2a-P(Ser51):eIF2a-T ratio
was found to be 150% of N control (p < 0.05). We next per-
formed linear regression analyses and determined that BACE1
level and amyloid load had a significant positive correlation in
human brain, as expected (p < 0.05; Figure 7G). Importantly,
BACE1 levels plotted against eIF2a-P(Ser51):eIF2a-T ratios
also showed a significant positive correlation (p = 0.0135; Fig-
ure 7E), suggesting that the increase in eIF2a-P might cause
the BACE1 elevation in human brain. Finally, amyloid load also
exhibited significant positive correlation with eIF2a-P:eIF2a-T
ratio (p < 0.01; Figure 7F), in further support of the hypothesis
that eIF2a-P promotes amyloidosis. Taken as a whole, our
5XFAD mouse and human AD results strongly suggest that
increased eIF2a phosphorylation plays a role in the elevation of
BACE1 levels in the brain and contributes to the development
of amyloid pathology.
DISCUSSION
Alzheimer’s disease is a complex neurodegenerative disorder
that can result from multiple environmental and genetic factors
that affect both the production and clearance of Ab in the
brain, the interaction of Ab with other proteins involved in AD
pathogenesis, the susceptibility of neurons to Ab toxicity, and
the susceptibility of neural systems to functional impairment
from neurodegeneration. Identification of the molecular mecha-
nisms underlying these processes is essential for the develop-
ment of rational therapeutics to treat or prevent this disorder.
Numerous studies have linked impaired energy metabolism to
AD (Craft and Watson, 2004; de Leon et al., 1983; Hoyer, 2004;
Rapoport, 1999a, b; Steen et al., 2005). Studies of postmortem
AD brains have also shown increased BACE1 levels compared
with age-matched, nondemented controls (Fukumoto et al.,
2002; Holsinger et al., 2002; Li et al., 2004; Sennvik et al., 2004;
Tyler et al., 2002; Yang et al., 2003; Zhao et al., 2007). Our results
indicate that these findings might be related. We showed previ-
ously that BACE1, the enzyme that initiates the amyloidogenic
pathway, is upregulated in response to acute energy deprivation
in vivo (Velliquette et al., 2005). Here, we show that the energy-
deprivation-induced BACE1 increase (1) occurs via a transla-
tional control mechanism that is dependent upon the BACE1
mRNA 50UTR; (2) is regulated by eIF2a phosphorylation, PERK
kinase, and the UPR/ER stress response; and (3) raises Ab
production and promotes amyloid plaque formation. In addition,1000 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.eIF2a phosphorylation positively correlates with increased
BACE1 levels and amyloid loads in humans with AD and in
5XFAD transgenic mice. We conclude that age-related impair-
ment of cerebral energy metabolism could induce eIF2a phos-
phorylation and increase BACE1 levels, thereby exacerbating
amyloidogenesis in AD. Thus, our results might have important
implications for both the initiation and progression of AD.
In sum, our experiments have excluded all possible mecha-
nisms of the energy-deprivation-induced BACE1 elevation,
except for an increase in translation. Importantly, we found no
evidence that the BACE1 increase involved BACE1 gene tran-
scription. In fact, we observed decreased BACE1 mRNA levels
in treated primary neuron cultures and mouse brains, clearly
demonstrating a posttranscriptional mechanism. The absence
of caspase 3 activation or BACE1 protein stabilization in our
energy-deprivation models indicates that the specific mecha-
nism of increased BACE1 level described in our study is distinct
from posttranslational mechanisms controlling BACE1 protein
levels (Tesco et al., 2007). Moreover, we have excluded a role
for miRNAs, although altered expression of specific miRNAs
might be an important posttranscriptional mechanism for the
regulation of BACE1 levels (Hebert et al., 2008; Wang et al.,
2008). Although our results indicate that the eIF2a-P pathway
is the only posttranscriptional mechanism controlling energy-
deprivation-induced BACE1 elevation, which might be relevant
to early amyloidogenesis in preclinical AD; in the later stages of
the disease, it is possible that other BACE1-elevating mecha-
nisms come into play, including microRNA dysregulation (Hebert
et al., 2008; Wang et al., 2008), apoptosis (Tesco et al., 2007),
and p25/cdk5 dysfunction (Cruz et al., 2006; Wen et al., 2008).
These other mechanisms might either act alone or in concert
to increase BACE1 levels and accelerate Ab production. Ab over-
production, in turn, might propagate the stress response in the
brain and exacerbate the progression of amyloid pathology by
feeding back and further elevating eIF2a-P levels.
Although the increase in Ab40 levels and plaque numbers in
2DG- and 3NP-treated Tg2576 mice did not quite reach a level
of statistical significance, there was clearly an increasing trend
that matched the relative potency of each compound for inhibit-
ing glucose metabolism (Figures 5D and 5E). This potency effect
also extended to the treatment-induced increases of BACE1 and
eIF2a-P (Figures 5D and 5E) and the decreases of BACE1 and
APP mRNA levels (Figure 6C) caused by the two drugs. Given
how slowly plaques form in Tg2576, it is likely that a longer treat-
ment period would have led to greater Ab accumulation and
subsequent statistical significance. Although complex and
poorly understood, plaque formation appears to be governed
by the balance between the production and degradation of Ab
in the brain. We excluded the possibility that increased amyloi-
dogenesis in treated Tg2576 mice was a consequence of either
increased PS1/g-secretase or decreased Ab-degrading
enzymes, IDE and NEP. On the contrary, the slight trend of
increased NEP level in 3NP-treated mice (Figure S7B) might
have partially limited the Ab increase in these animals. Regard-
less, the fact that both plaque number and Ab40 level show the
same relative increase as BACE1 and eIF2a-P in 2DG- and
3NP-treated mice suggests that energy deprivation is amyloido-
genic in vivo.
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of Cellular Stress
Many translationally regulated transcripts encode proteins that
appear to be involved in cellular stress responses. Although
the normal roles of APP and BACE1 are not well understood,
one of the proposed functions of BACE1, APP, and APP
cleavage fragments is that they might be involved in the
response to stress or injury (Blasko et al., 2004; Kamenetz
et al., 2003; Sambamurti et al., 2004; Tamagno et al., 2005; Ta-
nahashi and Tabira, 2001; Tesco et al., 2007; Turner et al., 2003;
Wen et al., 2004, 2008). One type of stress that appears to be
capable of altering APP processing and elevating Ab generation
is impaired energy metabolism (Busciglio et al., 2002; Gasparini
et al., 1997; Hoyer et al., 2005; Webster et al., 1998). Because
BACE1 levels are increased by energy deprivation, our data
lend further support to the hypothesis that BACE1 might play
a normal role in neuronal stress-response.
Stress-induced signaling pathways are typically thought to
activate downstream transcriptional targets; however, many of
these pathways also converge upon various components of
the cellular translation machinery (Holcik and Sonenberg,
2005; Pavitt, 2005; Schroder and Kaufman, 2006). It is becoming
increasingly evident that translation is a highly regulated process
that plays a crucial role in the cellular response to stress. The
most tightly controlled step in translation under stress conditions
is at the level of initiation. Phosphorylation of eIF2a at Ser51 is
a major mechanism for regulation of translation initiation in
response to various cellular stresses (reviewed in Clemens,
2001; Schroder and Kaufman, 2006).
eIF2a is known to be phosphorylated by at least four different
kinases, including double-stranded RNA-activated PKR, PERK,
GCN2, and HRI, in response to a variety of stress stimuli, such
as the unfolded protein response, amino acid deprivation, UV
irradiation, heat shock, viral infection, and hypoxia (Figure 8A,
right). Exchange of GDP for GTP on eIF2, a requirement for
formation of the eIF2$GTP$Met-tRNAi ternary complex, is cata-
lyzed by eIF2B (Figure 8A, left). Phosphorylation of eIF2a inhibits
the dissociation of eIF2B from eIF2a, thereby preventing the
exchange of GDP for GTP and reducing the rate of ternary
complex formation (Pavitt, 2005; Proud, 2001; Schroder and
Kaufman, 2006). Reduced availability of the ternary complex
simultaneously lowers the rate of global protein synthesis and
enhances the translation of mRNAs similar to BACE1 that are
normally translated at low levels due to long, G-C-rich, uORF-
containing 50UTRs (Figure 8B, right). Translational derepression
of these mRNAs can be mediated by phosphorylated eIF2a
through a variety of different mechanisms that overcome
50 UTR mRNA secondary structure (Figure S8B), inhibitory
uORFs (Figure S8A), or leaky ribosomal scanning (Pavitt, 2005;
Schroder and Kaufman, 2006).
Recent studies have demonstrated that the 50 UTR of BACE1
mRNA inhibits translation, implying that BACE1 might be trans-
lationally regulated. However, the specific mechanism respon-
sible for BACE1 translational repression has been a matter of
debate. It has been suggested that the 50 UTR of BACE1
mRNA forms a translational barrier as the result of tightly folded
secondary structure in the BACE1 50UTR (Lammich et al., 2004).
Alternatively, the three uORFs in the BACE1 mRNA 50UTR mightNinhibit ribosomes from reaching the authentic BACE1 ORF (De
Pietri Tonelli et al., 2004; Mihailovich et al., 2007). A related trans-
lational repression mechanism involving leaky scanning of ribo-
somes through the BACE1 mRNA 50 UTR and reinitiation at the
BACE1 ORF has also been proposed (Zhou and Song, 2006).
Finally, it has been suggested that ribosome shunting might
occur, thus allowing ribosomes to bypass the BACE1 mRNA 50
UTR (Rogers et al., 2004), although this mechanism is rare.
Although these studies suggested that BACE1 translational
control might play an important role in AD pathogenesis, it was
still an open question whether BACE1 translational repression
could be lifted under conditions of stress relevant to AD. More-
over, a potential role for the eIF2a-P pathway in the regulation
of BACE1 translation had not been considered. Here, for the first
time we provide evidence linking impaired energy metabolism,
an AD-relevant stress, to BACE1 translational derepression
mediated by eIF2a phosphorylation. It is well established that
phosphorylation of eIF2a can relieve translational repression
caused by secondary structure or uORFs in the 50 UTR, the
best-studied example being that of the yeast GCN4 gene (Pavitt,
2005; Schroder and Kaufman, 2006). The reduced concentration
of eIF2$GTP$Met-tRNAi ternary complex under conditions of
high eIF2a-P allows 40S ribosomal subunits to scan along the
50 UTR for a longer period before reloading with ternary complex
to form the 43S preinitiation complex. In this circumstance, 40S
subunits are more likely to bypass secondary structure and
uORFs in the 50 UTR, thereby increasing the probability that re-
loading will occur in close proximity to the major ORF and reini-
tiation of translation will happen at the authentic start codon
(Figure 8B, right). Our finding that the energy-deprivation-
induced BACE1 increase occurs via a translational mechanism,
and is dependent upon the BACE1 mRNA 50UTR and involves
eIF2a phosphorylation, as well as evidence that the BACE1
50UTR has extensive secondary structure with uORFs that inhibit
translation (Figure S8; Lammich et al., 2004), are all consistent
with a mechanism of eIF2a-P mediated translational derepres-
sion under conditions of cellular stress (Figure 8).
It is noteworthy that impaired energy metabolism in the form of
glucose deprivation had the common effect of increasing levels
of eIF2a-P and BACE1 in HEK293 cells, primary neurons, and
brains. The fact that different cell types responded similarly to
energy deprivation suggests that a ubiquitous stress-induced
pathway underlies the eIF2a-P increase. Our data indicate that
PERK is likely to be the major, if not only, eIF2a kinase respon-
sible for energy-deprivation-induced BACE1 elevation, at least
in vitro. Whether PERK is the eIF2a kinase responsible for the
BACE1 increase in 5XFAD transgenic mouse and AD human
brain remains to be determined. However, the involvement of
PERK in energy-deprivation-induced BACE1 elevation is
completely consistent with the well-established role of PERK in
the UPR, a ubiquitous protective mechanism found in all cells.
PERK is activated by unfolded proteins in the ER, and conse-
quent eIF2a phosphorylation concomitantly reduces global
protein synthesis and increases mRNA translation for a specific
subset of proteins that mediate the UPR. This protective mech-
anism prevents the accumulation of unfolded proteins that could
threaten the survival of the cell. Clearly, glucose deprivation or
other forms of deficient energy metabolism would reduce cellulareuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 1001
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Pathogenesis
(A) eIF2a phosphorylation determines the concentration of ternary complex and consequently the rate of translation initiation. Under normal or poststress condi-
tions (left), levels of phosphorylated eIF2a are kept at low levels in the cell due to expression of regulatory subunits of the phosphatase PP1 (GADD34 and CReP),
which complex with PP1 and direct PP1 phosphatase activity to eIF2a. The drug salubrinal is a selective inhibitor of the PP1 complex and prevents dephosphor-
ylation of eIF2a-P (Boyce et al., 2005). eIF2B, which catalyzes the exchange of GDP for GTP on the g subunit of eIF2, freely binds to and dissociates from un-
phosphorylated eIF2a in the eIF2 complex. In its GTP form, eIF2 assembles into a ternary complex along with methionine-charged tRNA (eIF2$GTP$Met-tRNAi).
The ternary complex binds to the 40S ribosomal subunit to form the 43S preinitiation complex, which is then capable of initiating translation at an AUG sequence
of the appropriate context on an mRNA transcript. Recognition of the start codon catalyzes GTP to GDP on eIF2, which is then released from the 40S subunit for1002 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc.
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induce the UPR, as has been previously shown (Lee, 2001).
This scenario is likely given that protein folding in the ER is highly
dependent upon ATP (Zhang and Kaufman, 2006). In addition,
we speculate that neurotoxic Ab oligomers or amyloid plaques
might also activate the UPR, thus accounting, at least in part,
for the eIF2a-P and BACE1 increases in 5XFAD mouse and
human AD brains.
Although our data favor PERK and the UPR, it is possible that
another kinase might be involved in the energy-deprivation-
induced BACE1 elevation in the brain: GCN2, which is activated
by amino acid deprivation in yeast and is the predominant eIF2a
kinase expressed in the brain (Costa-Mattioli et al., 2005). Alter-
natively, other regulatory proteins might be altered in order to
increase levels of eIF2a-P(Ser51), such as inhibition of constitu-
tive repressor of eIF2a phosphorylation (CReP), which
complexes with PP1 and is responsible for keeping eIF2a de-
phosphorylated under basal conditions (Jousse et al., 2003), or
GADD34, which dephosphorylates eIF2a-P during the return to
basal conditions following stress.
It is important to note that BACE1 is not expected to be the
only target of the eIF2a translational control pathway induced
by energy deprivation. Indeed, several mRNAs are translationally
derepressed by phosphorylated eIF2a, including activating tran-
scription factor 4 (ATF4), CAAT/enhancer binding protein
(C/EBP), and cationic amino acid transporter-1 (Cat-1; Schroder
and Kaufman, 2006). These molecules play beneficial roles in the
response to cellular stress. Similarly, BACE1 might also perform
a protective or repair function during acute neuronal stress or
injury, such as remyelination (Willem et al., 2006) or depressing
excitotoxic synaptic activity (Kamenetz et al., 2003). Although
eIF2a phosphorylation is expected to increase the translation
of several stress-response proteins under the conditions of
chronic energy deprivation, BACE1 is the only identified eIF2a
target that is directly involved in amyloidogenesis and is there-
fore the most relevant to AD pathophysiology.
The role of eIF2a phosphorylation in the brain during normal
and pathological physiology is not well understood. Studies
using gene-targeted mice indicate that eIF2a phosphorylation
plays a crucial role in normal neuronal function, especially in
synaptic plasticity through the activation of GCN2 (Costa-Mat-
tioli et al., 2005; Costa-Mattioli et al., 2007; Klann et al., 2004).
During pathology, activation of the eIF2a pathway occurs in
the brains of AD patients, APP transgenic mice, and mice under-
going pharmacologically induced seizures (this study; Carnevalli
et al., 2006; Peel and Bredesen, 2003). In addition, eIF2a phos-
phorylation is also associated with risk factors for AD, such as
atherosclerosis and traumatic brain injury (TBI) (Schroder and
Kaufman, 2006). Moreover, eIF2a phosphorylation and the
UPR appear to be activated in several neurodegenerative
diseases besides AD, including Parkinson’s disease (PD), Hun-
tington’s disease, and amyotrophic lateral sclerosis (Malhotra
and Kaufman, 2007; Paschen and Mengesdorf, 2005). AD and
PD are often comorbid (Braak et al., 2005; Mitchell, 1999), and
it is tempting to speculate they share an underlying primary
abnormality that might involve eIF2a phosphorylation. Also,
amyloid pathology and the risk of AD are increased in patients
who have TBI or temporal lobe epilepsy (Gaitatzis et al., 2004;
another cycle of translation initiation. When eIF2a-P levels are low, ternary complex concentration is high and normal mRNA transcripts with short 50 UTRs are
translated with high efficiency. However, transcripts like BACE1 with long, uORF-containing, secondary-structure-rich 50UTRs are inefficiently translated. Under
stress conditions (right), eIF2a is phosphorylated by one of four different kinases in response to various stimuli. In this case, eIF2B does not readily dissociate from
phosphorylated eIF2a in the eIF2 complex, inhibiting the exchange of GDP for GTP on the g-subunit of eIF2 and effectively reducing the concentration of ternary
complex. In this case, the translation of normal mRNA transcripts is inhibited, whereas transcripts with long, uORF-containing, structured 50UTRs are paradox-
ically translated with increased efficiency (derepression).
(B) Model for eIF2a phosphorylation-dependent derepression of BACE1 mRNA translation, based on yeast GCN4 mRNA translational regulation (Schroder and
Kaufman, 2006). The BACE1 50 UTR is 453 nucleotides long, has three uORFs (numbered boxes), and has predicted stable secondary structure with a free energy
of 215.3 kcal/mol (Lammich et al., 2004). uORF2 has been shown to be the major uORF that inhibits BACE1 mRNA translation under normal conditions (Mihai-
lovich et al., 2007; Zhou and Song, 2006). A stable stem-loop structure (indicated by the hair-pin) is predicted downstream of uORF 2 (Figure S5B). The AUGs of
the three ORFs are in favorable contexts, and reports indicate that they are translated (De Pietri Tonelli et al., 2004; Mihailovich et al., 2007; Zhou and Song, 2006).
In our model, ribosomes would bind to the BACE1 mRNA cap, scan down the 50 UTR, and initiate translation first at uORF1. After translation of uORF1 is termi-
nated and the 60S subunits dissociate, a proportion of 40S subunits remain attached and continue to scan along the BACE1 mRNA 50 UTR. Under normal condi-
tions, levels of phosphorylated eIF2a are low (left) and ternary complex concentrations are high. In this case, 40S subunits are efficiently reloaded with ternary
complexes, 43S preinitiation complexes are rapidly formed, and translation reinitiation occurs at uORF2. A rare proline codon at the 30 end of uORF2 (boxed P;
Figure S5A) and downstream stable secondary structure (Figure S5B) increase dissociation of ribosomes from the BACE1 mRNA, reducing the proportion of 40S
subunits that scan through the BACE1 mRNA 50 UTR and reach the authentic BACE1 start codon for reinitiation. As a consequence, translation of the BACE1 ORF
is inefficient under normal conditions. In contrast, under cellular stress conditions, phosphorylated eIF2a levels are high (right) and ternary complex concentra-
tions are low. Translation initiation is still predicted to occur first at uORF1. After termination of uORF1 translation, a proportion of 40S subunits remain attached
and continue scanning the 50 UTR, as in low eIF2a-P conditions. However, when eIF2a-P is high, decreased ternary complex availability causes the 40S subunit to
spend more time scanning before becoming reloaded to form the 43S preinitiation complex. As a result, a higher proportion of 40S subunits scan through
uORF2-3 and reach the authentic BACE1 AUG to reinitiate translation at the BACE1 ORF. Thus, BACE1 mRNA translation is more efficient under stress conditions
than normal.
(C) Common risk factors for AD such as age, high cholesterol, cardiovascular disease, traumatic brain injury, and ApoE4 genotype might lead to a state of
impaired energy metabolism in the brain. Reduced energy availability activates the eIF2a-P stress-response pathway in neurons. Phosphorylation of eIF2a
augments the translation of specific stress-response proteins such as BACE1. Increased production of these stress-response proteins presumably enhances
the ability of neurons to survive under low-energy conditions. However, if the stress persists, eIF2a phosphorylation and BACE1 levels remain chronically
elevated, leading to increased Ab production. Even a small increase in Ab generation might have a significant impact on amyloid accumulation over the many
years apparently required for AD development. Elevated Ab levels might, in turn, cause neuronal dysfunction and stress, feeding back and further activating
the eIF2a-P stress-response pathway. Over time, and in combination with other exacerbating factors such as impaired Ab clearance/degradation, Ab begins
to accumulate in the brain and plaques form. Ab accumulation might trigger downstream pathology, (e.g., tau hyperphosphorylation), ultimately leading to neuro-
degeneration associated with sporadic AD. UPR indicates unfolded protein response.Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 1003
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that exhibit deficiencies in energy metabolism. Impaired glucose
utilization is a well-established feature of AD, and AD risk factors
might all have the common effect of reducing energy metabolism
in the brain. It is interesting to note that impaired energy metab-
olism, which would be expected to activate the eIF2a pathway,
appears to be a common factor in several neurodegenerative
disorders. Neurodegeneration might result either directly or indi-
rectly from energy deficits in specific neuronal populations,
which in turn determine the pathology and symptoms of a partic-
ular disease (Beal, 1992; Soane et al., 2007). It is conceivable
that energy deprivation and the eIF2a phosphorylation pathway
could play a role in several neurodegenerative diseases,
although BACE1 elevation and amyloidogenesis might not be
significant in every case. Whether amyloid pathology is involved
in a particular disease might depend on the specific neuronal
population that is affected by energy deprivation and the eIF2a
pathway. In AD, amyloid plaques readily form in the cortex and
hippocampus but not in the cerebellum, indicating that neuronal
populations vary with respect to their propensity to form amyloid.
Although many neurodegenerative diseases might exhibit defi-
cits in energy metabolism and activation of the eIF2a pathway,
only a subset (e.g., AD, PD, TBI, epilepsy) might have amyloid
pathology because of the specific nature of the neuron popula-
tions involved and how they respond to energy deprivation.
Nevertheless, specifically for AD, our results strongly suggest
that energy deprivation and the eIF2a phosphorylation pathway
play major roles in the BACE1 increase observed in AD, and
that this BACE1 elevation promotes Ab production and
amyloidogenesis.
Chronic Neuronal Stress, eIF2a, and Amyloid Pathology
Phosphorylation of eIF2a is usually observed as a transient
event. In contrast, we found sustained elevations of phosphory-
lated eIF2a in our energy-deprivation models. Likewise, the
presence of elevated levels of eIF2a-P(Ser51) in the brains of
5XFAD mice and AD patients suggests that eIF2a can be chron-
ically phosphorylated. It is unclear whether chronic eIF2a-
P(Ser51) increases are important for cell survival under long-
term stress. The fact that up to 36 hr of glucose deprivation did
not cause cell death in vitro and that 3 months of chronic energy
deprivation did not induce neurodegeneration in our study
implies that chronic elevations of eIF2a-P(Ser51) might be neu-
roprotective. eIF2a-P might have a dual function in the brain:
(1) in response to acute stress, which affords the neuron the
advantage of rapid production of stress-response proteins;
and (2) in response to chronic stress, which might serve to down-
regulate energy-expensive processes such as global transcrip-
tion and translation, while producing stress-response proteins.
This might enable the neuron to survive under long-term stress
conditions. The ability to survive chronic stress might be partic-
ularly important in the brain, where neurons are not readily
replaced. From this standpoint, Ab accumulation and amyloid
pathology can be viewed as eventual downstream conse-
quences of chronic eIF2a-P(Ser51) and BACE1 elevations,
which themselves might be serving protective functions, at least
initially. However, over the decades that AD is likely to develop,
BACE1 and amyloid build up to the point that Ab-induced neuro-1004 Neuron 60, 988–1009, December 26, 2008 ª2008 Elsevier Incdegeneration begins. Interestingly, because various stresses are
capable of elevating eIF2a-P levels, multiple types of chronic
stress in the brain are potentially amyloidogenic. Importantly,
elevated eIF2a-P(Ser51) levels in 5XFAD mouse and human AD
brains suggest that chronic stress, BACE1, eIF2a-P(Ser51),
and Ab collaborate in a positive feedback loop in which amyloi-
dogenesis becomes amplified once Ab has accumulated to the
level that it is capable of initiating and sustaining a stress
response in the neuron (Figure 8C). This model also predicts that
once amyloid pathology is initiated, it is likely to progress at an
increasing rate, unless the amyloidogenic cycle is somehow
interrupted. Thus, eIF2a phosphorylation might be involved in
both the initiation and progression of sporadic AD. This hypoth-
esis highlights the importance of developing new preventative
and disease-modifying therapies for AD, especially those aimed
at inhibiting the generation and accumulation of Ab in the brain.
EXPERIMENTAL PROCEDURES
See Supplementary Experimental Procedures for additional methods details.
Human Brain Tissue, Amyloid Loads, and Linear Correlations
Postmortem frontal cortex tissues were obtained from AD (n = 9; 88.3 ± 4.1 yr)
and healthy (n = 13; 88.0 ± 4.8 yr) participants in the Rush Hospital Memory
and Aging Project (R01AG17917; Bennett, David A.; PI) after Rush University
IRB approval. To determine amyloid load, brain sections (20 mm) were stained
with anti-Ab total antibody (MO0872; 1:100; Dako, Carpentaria, CA) via DAB
immunohistochemistry, and amyloid staining was imaged and quantified
with a stereological mapping station (Leica DMRBE microscope; computer
with StereoInvestigator software version 5.00; MicroBrightField Inc, Colches-
ter, VT). A systematic random sampling scheme was used to capture video
images of amyloid-stained sections for quantitative analysis of plaque deposi-
tion using a custom algorithm previously described (Bennett et al., 2004). The
percent areas stained for each section were averaged, and those numbers
were used for amyloid loads in statistical analyses. BACE1 and eIF2a-P levels
in frontal cortex samples were measured by immunoblot analysis as described
below and expressed as percent of the mean of the normal control group.
Linear regressions and comparisons of means using the t test were performed
using GraphPad Prism and InStat software, respectively (GraphPad Software,
Inc., San Diego, CA).
Animals and Drug Treatments
Tg2576 (Taconic, Hudson, NY) and C57/BL6 (NIA, Bethesda, MD) mice were
administered single i.p. injections of 13 PBS (VEH), 1 g/kg 2DG (Sigma, St.
Louis, MO), or 80 mg/kg 3NP (Sigma) adjusted to pH 7.0, once a week begin-
ning at 9 months of age (8 or 9 mice per group). At 12 months of age, mice were
transcardially perfused, brains were excised and divided in half, and hemi-
brains analyzed by biochemistry or immunohistochemistry as described
below. Tg6799 ‘‘5XFAD’’ male mice were bred in-house to B6/SJL F1 hybrid
females (Taconic) and described previously (Oakley et al., 2006). All proce-
dures were carried out in accordance with the NIH Guide for the Care and
Use of Laboratory Animals and were approved by the Northwestern University
Animal Care and Use Committee.
Tissue Preparation for Biochemical Analysis
Hemibrains were flash frozen in liquid N2 and stored at 80C. Frozen mouse
hemibrains or human cortical samples were homogenized in 13 PBS, 1%
Triton X-100, 13 protease inhibitor cocktail (Calbiochem, San Diego, CA),
and 13Halt phosphatase inhibitor cocktail (Pierce, Rockford, IL). Total protein
concentration was determined by the BCA method (Pierce).
Human Ab40 ELISA
A total of 10 mg/ml Tg2576 brain homogenate was extracted overnight in 5 M
guanidine-HCl at room temperature (RT). Brains were further diluted 225-fold.
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at 16,000g for 20 min at 4C, then diluted two times with Ab diluent with 13
AEBSF. Tg2576 cell media was diluted in Ab diluent with 13 AEBSF. Total
Ab40 levels in diluted samples were determined using a human Ab40-specific
sandwich ELISA (Invitrogen, Carlsbad, CA) according to manufacturer’s
recommendations.
Amyloid Plaque Counts
A set of eight evenly spaced 30 mm parasagittal sections were selected that
spanned the entire medial-lateral dimension of each hemibrain from Tg2576
mice chronically treated with vehicle, 2DG, or 3NP. Sections were stained
with anti-Ab antibody 4G8, developed by DAB immunohistochemistry, coun-
terstained with hematoxylin, and mounted as described below. The total
number of amyloid plaques in the eight sections from each mouse was then
visually counted at low magnification in a microscope and plaque number
means, SEMs, and p values calculated.
Immunoblot Analysis
Total protein concentrations in cell lysates or brain homogenates were deter-
mined by the BCA method (Pierce). 1-25 mg protein from brain homogenates or
cell lysates were boiled in a 1:1 solution of SDS sample boiling buffer and 13
RIPA (cells) or homogenization buffer (brains) before being separated on 4%–
12% NuPAGE Bis-Tris gels in 13MOPS running buffer (Invitrogen) and trans-
ferred to Millipore Immobilon-P polyvinylidene difluoride (PVDF) membrane, as
described previously (Zhao et al., 2007). Blots were blocked in 5% bovine
serum albumin in Tris-buffered saline (TBS), 0.1% Tween 20 (TBST; Sigma)
overnight, then incubated in primary antibody for 1 hr at RT or overnight at
4C (a table of primary antibodies and dilutions is included in Supplementary
Experimental Procedures). Blots were washed in TBST and incubated for
1hr in horseradish peroxidase (HRP)-conjugated secondary antibodies diluted
1:10,000 in 5% milk in TBST (Jackson ImmunoResearch Laboratories, West
Grove, PA). Immunosignals were detected using enhanced chemilumines-
cence (ECL+, Amersham Biosciences, Piscataway, NJ, or SuperSignal West
Femto, Pierce) and quantified using a Kodak CF440 imager (Rochester, NY).
Densitometric analyses of immunoblots were performed using Kodak 1D 3.6
image analysis software. Immunosignals of phosphorylated proteins were
normalized to their respective total proteins. For other proteins, immunosig-
nals were normalized to b-actin immunosignal or were normalized per default
by adding the same amount of total protein loaded per lane, as indicated in
figure legends. Values were expressed as percentages of the mean of the
control. One microliter of a 1:10 dilution of BACE1-293 cell lysate was used
as a BACE1 positive control. Ten micrograms BACE1/ brain homogenate
was used as a BACE1 negative control, and 10 mg UV-treated 293 cell lysate
was used as a positive control for eIF2a-P, c-Jun-P, and JNK-P (Cell Signaling
Technology, Danvers, MA).
RNA Isolation and Real-Time PCR, and microRNA Analysis
Total RNA was isolated using RNeasy Mini kit (cells) or RNeasy Lipid Mini kit
(brains; Qiagen, Valencia, CA). For real-time PCR analysis, 1 mg total RNA
from each sample was used for first-strand cDNA synthesis using SuperScript
III (Invitrogen). A total of 112.5 ng cDNA from each sample was amplified via
real-time PCR using assays-on-demand premixed Taqman primer/probe set
for mouse or human BACE1 and mouse APP mRNA, and normalized against
18 s rRNA, using an 7900HT sequence analyzer (Applied Biosystems, Foster
City, CA). mRNA levels for each experimental group were quantified using
the comparative CT method. For microRNA analysis, RNA samples were
analyzed using the Taqman microRNA reverse transcription kit with Taqman
Universal PCR master mix (Applied Biosystems). Quantitative real-time PCR
procedures were performed as previously described (Hebert et al., 2008)
following the manufacturer’s recommendations (Applied Biosystems). Rela-
tive expression was calculated by using the comparative CT method.
Immunohistochemistry
Hemibrains were drop-fixed in 4% paraformaldehyde, 13 PBS overnight and
equilibrated in 30% sucrose in 13 PBS with 0.01% sodium azide at 4C for at
least 12 hr for histology. Frozen parasagittal sections (30 mm) from cryopre-
served brains were cut using a sliding microtome and collected in TBS.NSections from Tg2576 brains were stained with Thioflavin S (for b sheet
amyloid) or incubated in anti-4G8 (1:5000; Chemicon) overnight at room
temperature, washed, and incubated with biotinylated secondary antibody
(1:5000; Chemicon) for 1 hr. The Vectorlabs ABC kit was used with DAB as
chromogen to visualize the reaction product for 4G8, and sections were coun-
terstained with hematoxylin. The total number of 4G8-positive plaques in each
section was counted manually and average number of plaques per section
was calculated (8-11 sections/mouse). Sections from C57/BL6 brains were
stained with cresyl violet to verify that chronic energy inhibitor treatments
did not cause neurodegeneration or neuron loss. Sections were mounted, cov-
erslipped, and imaged using a Nikon Eclipse E800 microscope and Spot
advanced digital camera (Diagnostic Instruments, Sterling Heights, MI).
Cell Line Cultures
pCMV-hBACE1 was created by subcloning BACE1 cDNA (accession number
AF190725) into the expression vector pCMVi (Cellular & Molecular Technolo-
gies, Inc., Lavallette, NJ). The BACE1-293 cell line was generated by co-trans-
fecting HEK293 cells with pCMV-hBACE1 and pRSV-Puro and selecting with
5 mg/ml puromycin (Sigma), and were maintained in selective DMEM (Invitro-
gen) containing D-glucose (4500 mg/l). For energy-deprivation experiments,
cells were incubated in selective DMEM without glucose (Invitrogen). Transient
transfections in BACE1-293 and HEK293 cells were performed using Lipofect-
amine 2000 (Invitrogen). GADD34DN, PERKDN, GCN2DN, and P58IPK vectors
were gifts from David Ron (New York University). The +50UTR and 50UTR
BACE1 constructs have been described previously (Lammich et al., 2004). Sa-
lubrinal (Calbiochem) was added to the cell media at 100 mM for 24 hr. Actino-
mycin D (Sigma) was added to the cell media at 1.7 mg/ml for 12 hr. For tauro-
deoxycholate (TUDCA; Sigma) experiments, cells were pretreated with 1 mM
TUDCA (adjusted to pH 7.0) for 30 min, then treated for 12 hr with glucose-defi-
cient media containing 1 mM TUDCA. For biochemical analyses, cells were
lysed in 13 RIPA buffer with 13 protease inhibitor and 13 Halt phosphatase
inhibitor cocktails, and protein content was measured using the BCA assay
(Pierce).
Pulse-Chase
BACE1-293 cells were grown in 10 cm plates. Before pulse-labeling, cells were
incubated in methionine/cysteine-deficient DMEM (MP Biochemicals, Solon,
OH) for 1 hr. Cells were pulse-labeled with 2 ml methionine/cysteine-deficient
DMEM supplemented with 0.2mCi 35S trans-labeled methionine and cysteine
(MP Biochemicals) for 20 min. Cells were washed two times and ‘‘chased’’ with
regular DMEM (Invitrogen). At 0, 3, 6, 12, and 24 hr after labeling, lysates were
homogenized in 13 RIPA and immunoprecipitated with Sepharose G beads
(Amersham, Buckinghamshire, UK) and 3 mg anti-BACE1 (PA1-757; Affinity
Bioreagents, Golden, CO). Immunoprecipitates were separated using 10%
Criterion Tris-HCl gels (BioRad, Hercules, CA). Gels were fixed, dried, and
exposed to a phosphor screen overnight (Amersham). Autoradiographic
signals were imaged using a Cyclone Plus Phosphor Imager (Perkin-Elmer,
Waltham, MA).
Neuronal Cultures
Cortical tissue was isolated from E15.5-E16.5 C57/BL6 embryos, dissociated
for 15 min at 37C in 5 ml 0.25% trypsin (Invitrogen), washed with 13BSS, and
triturated. Neurons were plated for 2 hr in serum-containing neurobasal media
supplemented with B-27 (Invitrogen). Neurons were maintained for 2 DIV in
neurobasal media without serum. At 2 DIV, neurons were switched to neuro-
basal media without glutamate, after which half of the maintenance media
was changed every 2 or 3 days. Treatments began at 7 DIV. For energy depri-
vation experiments, neurons were treated for 36 hr in Locke’s solution with or
without 20 mM glucose (Cheng and Mattson, 1995). For pharmacological
treatments, Sal was added to the media at 50 mM or 80 mM for 48 hr, and
rapamycin (Cell Signaling) was added to the maintenance media at 10 nM
for 12 hr. For biochemical analyses, media and cell lysates were collected,
and lysates were analyzed for total protein content using the BCA assay.
Statistical Analysis
Data are presented as means and standard errors of the mean (SEMs, repre-
sented by error bars in histograms). N-values are stated in figure legends.euron 60, 988–1009, December 26, 2008 ª2008 Elsevier Inc. 1005
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was determined using the two-tailed t test (*p < 0.05, **p < 0.01, ***p < 0.001).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Table S1,
and Figures S1–S8 and can be found with this article online at http://www.
neuron.org/supplemental/S0896-6273(08)00947-1.
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